Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
A vancomycin-class glycopeptide, produced as several related A2 components, that caps cell-wall precursors.
Also known as: teichomycin A2 · Targocid
Part of the Foundational & therapeutic peptides cluster
Overview
Teicoplanin is a glycopeptide antibiotic complex first isolated in 1978 from Actinoplanes teichomyceticus, sharing the mechanism of vancomycin. It binds the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking and blocking Gram-positive cell-wall synthesis. Marketed as Targocid in many countries (not the U.S.), it treats serious infections including MRSA. This page is educational and not medical advice.
Source & context
Biological / chemical source: Soil actinomycete Actinoplanes teichomyceticus
Primary research or clinical context: Approved (outside the U.S.) antibiotic for serious Gram-positive infections
Structure and mechanism
Teicoplanin is a mixture of closely related components (A2-1 to A2-5) built on a glycosylated heptapeptide core with a lipid side chain. By binding the D-Ala-D-Ala end of the growing peptidoglycan, it sterically blocks the transpeptidation and transglycosylation steps of cell-wall assembly in Gram-positive bacteria.
Clinical profile
Its long half-life allows once-daily dosing, and it is used for endocarditis, bone and soft-tissue infections and MRSA. Teicoplanin is approved across Europe, Asia and South America but not by the U.S. FDA. Research has also examined glycopeptides for antiviral entry inhibition. This page is educational only.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Teicoplanin (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C88H97Cl2N9O33
- Average reference mass
- ≈ 1,879.7
- Status
- Approved medicine in at least one jurisdiction (IUPHAR record)
- PubChem CID: 133065662
- IUPHAR ligand: 10924
- DrugBank: DB06149
- CAS RN: 61036-62-2
- UNII: 4U3D3YY81M
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 44 registered studies with “Teicoplanin” as an intervention (snapshot 2026-10-01). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT06426836 | Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO) | Not applicable | recruiting | 2026-09-21 |
| NCT02456974 | Antibiotic Dosing in Pediatric Intensive Care | — | recruiting | 2026-09-17 |
| NCT00368537 | Study Comparing the Safety and Efficacy of Tigecycline With Ampicillin-Sulbactam or Amoxicillin-Clavulanate to | Phase 4 | completed | 2026-09-15 |
| NCT05914467 | TDM-optimized Teicoplanin Dosing Versus Standard of Care | Phase 4 | terminated | 2026-08-12 |
| NCT07590648 | Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia | Phase 4 | not yet recruiting | 2026-05-15 |
| NCT05074147 | Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHR | Phase 3 | withdrawn | 2026-01-14 |
Teicoplanin — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Teicoplanin (source record; form not independently established)Average reference mass: 1,879.7 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Teicoplanin
What is Teicoplanin?+
Teicoplanin is a glycopeptide antibiotic complex first isolated in 1978 from Actinoplanes teichomyceticus, sharing the mechanism of vancomycin. It binds the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking and blocking Gram-positive cell-wall synthesis. Marketed as Targocid in many countries (not the U.S.), it treats serious infections including MRSA. This page is educational and not medical advice.
What Canadian product status is recorded for Teicoplanin?+
Canadian product status for Teicoplanin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Teicoplanin?+
Teicoplanin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
Related peptides
References & further reading
- 1.Shea et al. (1995). Teicoplanin. Med Clin North Am
- 2.Trautmann et al. (1994). Teicoplanin: 10 years of clinical experience. Infection
- 3.Parenti et al. (2000). Teicoplanin Chemistry and Microbiology. J Chemother
- 4.Greenwood (1988). Microbiological properties of teicoplanin. J Antimicrob Chemother
- 5.Furuta et al. (2004). [Glycopeptides (vancomycin, teicoplanin)]. Nihon Rinsho
- 6.García-Gómez et al. (2020). LC-HRMS based on mixed-mode chromatography for the separation of teicoplanin and the unravelment of its composition. J Pharm Biomed Anal
- 7.Babul et al. (1988). Teicoplanin: a new glycopeptide antibiotic complex. Drug Intell Clin Pharm
- 8.Cavalcanti et al. (2010). Teicoplanin versus vancomycin for proven or suspected infection. Cochrane Database Syst Rev
- 9.PubChem — compound summary for Teicoplanin (CID 133065662)
- 10.Wikipedia — Teicoplanin